Page 19 - சுயாதீனமான தகவல்கள் கண்காணிப்பு குழு News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Sanofi continued its growth trajectory Strong increase in Q1 2021 business EPS(1) at CER
einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.
Investegate |GlaxoSmithKline PLC Announcements | GlaxoSmithKline PLC: 1st Quarter Results
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Tagrisso moves closer towards EU approval for early-stage lung cancer
27th April 2021
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca’s (AZ) Tagrisso for approval in the EU for the treatment of early-stage lung cancer patients.
Specifically, the CHMP has recommended a marketing authorisation for Tagrisso (osimertinib) for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour resection.
The positive opinion is based on results from the Phase III ADAURA trial, in which Tagrisso demonstrated a statistically significant improvement in disease-free survival in the primary analysis population of patients with early-stage EGFRm NSCLC.
April 27, 2021
SALT LAKE CITY and TOKYO, April 27, 2021 /PRNewswire/ DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it has completed enrollment in its Japanese safety study of IDCT, an allogeneic, injectable Discogenic Cell therapy for lumbar disc degeneration, a major cause of chronic low back pain.
Injectable Disc Cell Therapy (IDCT) is a non-surgical study treatment for lumbar disc degeneration.
This Japanese 38-subject trial is being conducted at seven sites across the Country and passed the first of two planned mid-trial safety reviews by an Independent Data Monitoring Committee (IDMC). All treated subjects will be observed and evaluated for safety, primary efficacy, and secondary outcome measures for a period of six months, at which time another IDMC review will be completed. Per the study
Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Tagrisso adjuvant receives positive CHMP opinion
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.